Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2013

View Archived Issues

Mayo Clinic licenses patient-derived xenograft models of cancer to WuXi PharmaTech

Tricyclo-DNA oligonucleotides show promise for SMA and DMD

Swedish Orphan Biovitrum provides update on pipeline candidates

Daiichi Sankyo updates pipeline progress of second quarter of fiscal 2013

Biomarker predicts exacerbations in cystic fibrosis patients

AB Pharma and Zannan SciTech identify novel HCV NS5A inhibitors

First patient enrolled in Serodus' phase IIa trial of SER-100

Phase II trial of Zerenex in NDD-CKD meets all primary and key secondary endpoints

IDMC recommends continuation of Cel-Sci's pivotal trial of Multikine

Omeros reports data for OMS-721 from model of age-related macular degeneration

AEterna Zentaris submits NDA to FDA for macimorelin acetate

Five Prime Therapeutics licenses proprietary antibodies to ADC Therapeutics

Trophos completes pivotal phase II/III study of olesoxime in spinal muscular atrophy in Europe

Inducers of immune tolerance increased in cystic fibrosis airway neutrophils

Ajinomoto reports phase IIa results for AJM-300 in ulcerative colitis

Takeda reviews highlights of second quarter of fiscal 2013

GE Healthcare tests novel PET tracers for evaluating traumatic brain injury

Novogen and Yale University create joint venture to develop drugs for ovarian cancer

Prima Biomed grants CVac license to Neopharm for Israel

Researchers in the U.S. and Taiwan present new ganciclovir prodrugs

Cancer Research Technology reports novel CDK9 inhibitors for cancer

U.S. team synthesizes new anticancer agents

Novel arginase inhibitors synthesized by Mars

Biota Scientific Management discloses new NS5B inhibitors for HCV infection

Novo Nordisk presents pipeline developments of third quarter 2013

New phase II study investigates ADI-PEG-20 for relapsed or refractory AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...